Landmark TrialOther
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
New England Journal of Medicine2018IF: 25.4
Jae H. Park, Isabelle Rivière, Mithat Gönen, Xiuyan Wang, Brigitte Sénéchal, Kevin J. Curran, Craig S. Sauter, Yongzeng Wang, Bianca Santomasso, Elena Mead, Mikhail Roshal, P. Maslak, Marco L. Davila, Renier J. Brentjens, Michel Sadelain
Abstract
In the entire cohort, the median overall survival was 12.9 months. Among patients with a low disease burden, the median overall survival was 20.1 months and was accompanied by a markedly lower incidence of the cytokine release syndrome and neurotoxic events after 19-28z CAR T-cell infusion than was observed among patients with a higher disease burden. (Funded by the Commonwealth Foundation for Cancer Research and others; ClinicalTrials.gov number, NCT01044069 .).